АВИЛА Клаудио (CH),КРАББЕ Рафаэль (CH),НАУМОВ Николай (CH)
申请号：
RU2013120345/15
公开号：
RU2013120345A
申请日:
2011.10.03
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. Alisporivir for use in the treatment of patients infected with hepatitis C virus with genotypes 2 or 3, characterized in that (i) alisporivir is administered during the initial phase in an amount of approximately 600 mg twice a day； (ii) followed by the administration of alisporivir during the second phase in an amount of at least about 600 mg once a day. Alisporivir for use according to claim 1, wherein alisporivir is administered during the second phase in an amount of from about 600 mg to about 1000 mg once a day. Alisporivir for use according to claim 1, wherein alisporivir is administered during the second phase in an amount of 600 mg or approximately 800 mg once daily, and where alisporivir is administered in combination with ribavirin or standard therapy throughout the initial phase and second phase during treatment 12 weeks. 4. Alisporivir for use according to claim 3, wherein the patient is a patient with no response to treatment. Alisporivir for use according to claim 1, where (i) alisporivir is administered in the initial phase in an amount of 600 mg twice a day for 7 days in combination with ribavirin； (ii) followed by the administration of alisporivir in the second phase in an amount of approximately 600 mg or 800 mg once a day for 3 weeks, for 5 weeks or for 7 weeks, in combination with ribavirin, and (iii) if HCV RNA is the patient's plasma can be detected by analysis of HCV RNA after stage (ii), then alisporivir must be administered in an amount of 600 mg once a day in combination with ribavirin and interferon for up to 24 weeks. A method for the treatment of patients infected with hepatitis C virus with genotypes 2 or 3, including the introduction of alisporivir during1. Алиспоривир для применения при лечении пациентов, инфицированных вирусом гепатита С с генотипами 2 или 3, отличающийся тем, что (i) алиспоривир вводят в течение начальной фазы в количестве приблизительно 600 мг дважды в сутки； (ii) с последующим введением алиспоривира в течение в
